INT48234

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.57
First Reported 1993
Last Reported 2010
Negated 0
Speculated 0
Reported most in Abstract
Documents 11
Total Number 13
Disease Relevance 3.97
Pain Relevance 6.25

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleolus (PTAFR) plasma membrane (PTAFR) nucleus (PTAFR)
signal transducer activity (PTAFR)
Anatomy Link Frequency
platelet 4
neutrophils 4
eosinophils 2
PTAFR (Homo sapiens)
Pain Link Frequency Relevance Heat
substance P 81 100.00 Very High Very High Very High
antagonist 54 100.00 Very High Very High Very High
Inflammation 200 99.60 Very High Very High Very High
agonist 20 99.50 Very High Very High Very High
adenocard 20 99.14 Very High Very High Very High
interstitial cystitis 4 99.14 Very High Very High Very High
diclofenac 6 99.12 Very High Very High Very High
cINOD 28 98.88 Very High Very High Very High
Inflammatory mediators 43 97.76 Very High Very High Very High
calcitonin gene related peptide 48 95.04 Very High Very High Very High
Disease Link Frequency Relevance Heat
INFLAMMATION 246 99.60 Very High Very High Very High
Interstitial Cystitis 4 99.14 Very High Very High Very High
Adhesions 7 96.64 Very High Very High Very High
Gastroesophageal Reflux Disease 36 96.16 Very High Very High Very High
Esophageal Disease 66 94.48 High High
Inflammatory Bowel Disease 66 83.36 Quite High
Injury 16 83.32 Quite High
Cancer 8 62.56 Quite High
Necrosis 4 62.08 Quite High
Disease 28 61.68 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Out of the other NSAIDs, diclofenac (which is chemically related to fenamates) suppressed degranulation as well as LTB4 and PAF production.
Negative_regulation (suppressed) of Gene_expression (production) of PAF associated with cinod and diclofenac
1) Confidence 0.57 Published 1994 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 7708126 Disease Relevance 0.13 Pain Relevance 0.81
Tolfenamic and meclofenamic acids were the most potent fenamates to inhibit PAF synthesis (IC50s 37 and 51 microM) as well as migration towards LTB4 (IC50s 61 and 92 microM).
Negative_regulation (inhibit) of Gene_expression (synthesis) of PAF
2) Confidence 0.57 Published 1994 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 7708126 Disease Relevance 0.14 Pain Relevance 0.76
For neutrophils, it has been shown that PAF synthesis is inhibited by cAMP.
Negative_regulation (inhibited) of Gene_expression (synthesis) of PAF in neutrophils
3) Confidence 0.57 Published 1996 Journal Eur Respir J Suppl Section Abstract Doc Link 8871060 Disease Relevance 0.08 Pain Relevance 0.20
Nimesulide also decreases histamine release from tissue mast cells and inhibits the production of platelet-activating factor by human basophils.
Negative_regulation (inhibits) of Gene_expression (production) of platelet-activating factor in platelet
4) Confidence 0.54 Published 1993 Journal Drugs Section Abstract Doc Link 7506193 Disease Relevance 0.16 Pain Relevance 0.32
Indomethacin inhibited LTB4 and PAF synthesis whereas ketoprofen reduced degranulation.
Negative_regulation (inhibited) of Gene_expression (synthesis) of PAF
5) Confidence 0.42 Published 1994 Journal Naunyn Schmiedebergs Arch. Pharmacol. Section Abstract Doc Link 7708126 Disease Relevance 0.13 Pain Relevance 0.81
However, at comparable concentrations, only nimesulide was able to inhibit the synthesis of PAF and LTC4 in activated eosinophils.
Negative_regulation (inhibit) of Gene_expression (synthesis) of PAF in eosinophils
6) Confidence 0.41 Published 1996 Journal Eur Respir J Suppl Section Abstract Doc Link 8871060 Disease Relevance 0.07 Pain Relevance 0.18
Because the design of selective PLA(2) inhibitors may provide a useful therapeutic strategy to reduce the inflammatory process in IC, we tested several frequently used PLA(2) inhibitors on PAF production in tryptase-stimulated HBMEC.
Negative_regulation (inhibitors) of Gene_expression (production) of PAF associated with inflammation and interstitial cystitis
7) Confidence 0.38 Published 2005 Journal J. Pharmacol. Exp. Ther. Section Abstract Doc Link 15937147 Disease Relevance 0.67 Pain Relevance 0.50
CONCLUSIONS: Local anesthetics in clinically relevant concentrations inhibit superoxide anion production of PAF-primed hPMNs.
Negative_regulation (inhibit) of Gene_expression (production) of PAF
8) Confidence 0.34 Published 2001 Journal Anesthesiology Section Body Doc Link 11465548 Disease Relevance 0 Pain Relevance 0
When the mucosal sac is filled with HCl at the same pH, however, its supernatant almost abolishes contraction in response to EFS and the inhibition is suppressed by PAF antagonists.
Negative_regulation (suppressed) of Gene_expression (antagonists) of PAF associated with antagonist
9) Confidence 0.31 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.30 Pain Relevance 0.47
Since cellular immune infiltrate is a prerequisite for severe inflammation and tissue damage, inhibition of IL-8, SP and PAF-induced PBL migration and activation may provide potential targets for therapy.


Negative_regulation (inhibition) of Gene_expression (migration) of PAF associated with inflammation and substance p
10) Confidence 0.31 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.59 Pain Relevance 0.65
In contrast, a PAF antagonist and a neurokinin-1 receptor antagonist (ie, SP antagonist) significantly reduce supernatant-induced H2O2 production.
Negative_regulation (reduce) of Gene_expression (antagonist) of PAF associated with antagonist and substance p
11) Confidence 0.31 Published 2010 Journal Journal of Neurogastroenterology and Motility Section Body Doc Link PMC2978390 Disease Relevance 0.34 Pain Relevance 0.74
Endogenous adenosine and A2AR agonists have shown to be potent inhibitors of leukotriene and platelet-activating factor synthesis [13], [18]–[20] and in contrast, to stimulate COX-2 expression in neutrophils [21], [22], thus increasing the capacity of these cells to produce prostaglandin E2.
Negative_regulation (inhibitors) of Gene_expression (synthesis) of platelet-activating factor in neutrophils associated with adenocard and agonist
12) Confidence 0.09 Published 2009 Journal PLoS ONE Section Body Doc Link PMC2654409 Disease Relevance 0.81 Pain Relevance 0.54
Other processes described include inhibition of platelet activating factor and production of oxygen radicals and other anti-inflammatory factors (Egan et al 1999; Hanauer 2004).
Negative_regulation (inhibition) of Gene_expression (production) of platelet activating factor in platelet associated with inflammation
13) Confidence 0.03 Published 2007 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC2376091 Disease Relevance 0.56 Pain Relevance 0.27

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox